<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab11">
 <label>Table 28.11</label>
 <caption>
  <p>Adverse effects associated with different classes of antiretroviral</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Class</th>
    <th>Drug</th>
    <th>Adverse effects</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="4">NRTIs</td>
    <td>Zidovudine</td>
    <td>Anemia, nausea, rash, myopathy, dyslipidemia</td>
   </tr>
   <tr>
    <td>Stavudine, didanosine</td>
    <td>Nausea, lipoatrophy, dyslipidemia, pancreatitis, lactic acidosis, hepatic steatosis</td>
   </tr>
   <tr>
    <td>Abacavir</td>
    <td>HSR, hepatotoxicity</td>
   </tr>
   <tr>
    <td>Tenofovir</td>
    <td>Renal insufficiency, bone loss</td>
   </tr>
   <tr>
    <td rowspan="3">NNRTIs</td>
    <td>Efavirenz</td>
    <td>CNS adverse effects, rash, hepatotoxicity, teratogenicity, hypertriglyceridemia</td>
   </tr>
   <tr>
    <td>Nevirapine</td>
    <td>HSR, rash, hepatotoxicity,</td>
   </tr>
   <tr>
    <td>Etravirine</td>
    <td>Rash, hepatotoxicity</td>
   </tr>
   <tr>
    <td rowspan="3">PIs</td>
    <td>All PIs</td>
    <td>Nausea, rash, hepatotoxicity, dyslipidemia, diarrhea, insulin resistance</td>
   </tr>
   <tr>
    <td>Atazanavir</td>
    <td>Jaundice, sclera icterus, nephrolithiasis</td>
   </tr>
   <tr>
    <td>Lopinavir, fosamprenavir</td>
    <td>Heart disease</td>
   </tr>
   <tr>
    <td>Integrase inhibitors</td>
    <td>Raltegravir</td>
    <td>Headache, insomnia, dizziness, fatigue</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
